Drugs and FDA

Celldex stops developing barzolvolimab for eczema after Phase 2 setback

Celldex will stop developing barzolvolimab for eczema after a Phase 2 study failed to meet the company's internal hurdle rate.

Reported by 2 outlets Saturday, November 21, 2026

Pink tablets in a blister pack
Photo: CC0

Celldex Therapeutics will stop developing barzolvolimab as an eczema treatment after the drug did not meet the company's internal hurdle rate in a Phase 2 study, the company said, according to BioPharma Dive. Endpoints News reported that the monoclonal antibody failed to reduce itching in patients with eczema compared with placebo.

Celldex is continuing development of barzolvolimab for chronic spontaneous urticaria, a form of chronic hives. BioPharma Dive reported that the drug succeeded in two late-stage trials for that condition and that Celldex is planning an approval filing. The eczema setback follows Phase 2 results in two other immune conditions that also fell short, the outlet reported. Wall Street analysts described the eczema result as immaterial to their investment view, according to BioPharma Dive.

Reporting on this story

More top stories

This Week in Medicine

The week in medicine, in five minutes

The most important medical news of the week, summarized for you and easy to read. Every Sunday, free.

Free. No spam. Unsubscribe anytime.